Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMGC936 in advanced solid tumors
NCT04622774Phase 2Completed
- Sponsor
- ImmunoGen
- Start
- Oct 2020
- Primary completion
- Dec 2023
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 3
01
Overview
Phase 2, open-label trial of izeltabart tapatansine in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC) and 3 more (10 arms), sponsored by ImmunoGen. Primary endpoints: Treatment-Emergent Adverse Events up to 3 years, Dose-Limiting Toxicities at Cycle 1 and 1 more. Started Oct 2020; status: completed.
02
Drugs
izeltabart tapatansine
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)colorectal cancer (CRC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT04622774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04622774.